Astria Therapeutics (ATXS) announced final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from ...

Researchers identified 13 plasma proteins linked to brain aging, uncovering dynamic patterns and biomarkers for early ...

Brain age gap (BAG) is a useful metric because it predicts one’s age-adjusted vulnerability to a range of neurological disorders, such as AD, dementia, and stroke. Although brain age may indeed ...

Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on KalVista Pharmaceuticals (KALV – Research Report). The ...

CAMBRIDGE, Mass. & SALISBURY, England-- (BUSINESS WIRE)--Dec 5, 2024-- ...

I broadly divided this into three classes: “plasma kallikrein inhibitors, bradykinin B2 receptor antagonists, and C1 Esterase Inhibitors, and two types — preventive treatments which are ...

In a phase 1 trial, Sebetralstat was shown to be able to suppress plasma kallikrein activity nearly completely. A single 600 mg dose of Sebetralstat produced a 98% inhibition of plasma kallikrein ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

One capsule of Orladeyo per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to ...

And other key secondary endpoints included safety, the number of angioedema attacks per month from weeks 5 to 16, and change from baseline in total plasma kallikrein protein level. A total of 27 ...